12:00 AM
Aug 05, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Etirinotecan pegol: Completed Phase III enrollment

Nektar completed enrollment of about 840 patients previously treated with cytotoxic chemotherapy regimens in the open-label, international Phase III BEACON trial comparing 145 mg/m 2 IV etirinotecan pegol once every 3...

Read the full 132 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >